The drug industry is bracing for the Trump administration’s planned tariffs on pharmaceutical products and ingredients, warning of supply chain [...] …
Blog Posts
Q: Tell us some interesting details about your company’s history.
RxParadigm, founded by industry veteran Mesfin Tegenu, is dedicated to developing technology solutions that streamline the drug supply chain and
…
The leaders of four health systems recently met with Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The U.S. Department of Health and Human Services (HHS) is continuing its pushback against drugmaker attempts to unilaterally convert upfront [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Minnesota covered entities will have additional 340B reporting requirements this year, but an extended deadline to submit that data, according [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An influential drug industry trade group on Friday sued Utah over its 340B contract pharmacy access law, marking the third [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
On April 9th, Nebraska Gov. Jim Pillen (R) signed a comprehensive 340B contract pharmacy access law that went into effect [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
President Donald Trump’s (R) preliminary budget appears to call for “new authority to regulate all aspects of the 340B program,” [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Both chambers of the Tennessee Legislature yesterday passed a scaled-back contract pharmacy access bill that would block manufacturers from placing [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Hospital and health center leaders are pushing back against President Donald Trump’s (R) new executive order, criticizing its controversial 340B [...] …